Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

April 8, 2024

https://www.globenewswire.com/news-release/2024/04/08/2859008/0/en/Positive-Results-from-Phase-3-OPTIMIZE-1-Trial-of-Once-Daily-OCS-01-for-the-Treatment-of-Inflammation-and-Pain-Following-Cataract-Surgery-Presented-at-the-2024-American-Society-of-.html

ZUG, Switzerland and BOSTON, April 08, 2024 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq:OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Eric Donnenfeld, M.D., presented the positive results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place April 5-8, 2024, in Boston, MA.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.